Evidence map›Paper›PMID 37316798›Full record

ReviewBMC nephrology2023

Piperacillin-tazobactam induced immune hemolytic anemia led to increased renal impairment and eventual death from multiple organ failure in a patient with hypertensive nephropathy: case report and literature review.

Yong Wu, Yuanjun Wu, Ganping Guo, Jiajun Zeng, Yan Liu, Yueqin Wu

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yong Wu *Department of Blood Transfusion, Dongguan Tungwah Hospital, Dongguan, China.
Yuanjun Wu *Department of Blood Transfusion, Dongguan Maternal and Child Health Hospital, Dongguan, China. wuyuanjun199@126.com.ORCID 0000-0002-9459-9688
Ganping GuoDepartment of Blood Transfusion, Dongguan Maternal and Child Health Hospital, Dongguan, China.
Jiajun ZengDepartment of Blood Transfusion, Dongguan Maternal and Child Health Hospital, Dongguan, China.
Yan LiuDepartment of Blood Transfusion, Dongguan Tungwah Hospital, Dongguan, China.
Yueqin WuDepartment of Blood Transfusion, Dongguan Tungwah Hospital, Dongguan, China.
Dongguan People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPiperacillin is one of the most common drugs that cause drug-induced immune hemolytic anemia, but a complete description of the serological features and course of the disease is rare. This study completely describes the serological characteristics and course of a patient with hypertensive nephropathy who developed drug-induced immune hemolytic anemia and worsened renal function during repeated administration of piperacillin-tazobactam. CASE PRESENTATION: A 79-year-old male patient with hypertensive nephropathy who developed severe hemolytic anemia and worsened renal function during intravenous piperacillin-tazobactam anti-infective treatment due to lung infection. Serological tests showed that the result of the direct antiglobulin test for anti-IgG was positive (4 +) and anti-C3d was negative, and the irregular red blood cell antibody screening test was negative. Plasma samples collected at different times from 2 days before to 12 days after the discontinuation of piperacillin-tazobactam administration were incubated with piperacillin solution and red blood cells of O-type healthy blood donors at 37 °C, IgG piperacillin-dependent antibodies were detected, and the highest titer was 128. However, no tazobactam-dependent antibody was detected in any plasma samples. Therefore, the patient was diagnosed with piperacillin-induced immune hemolytic anemia. Although blood transfusion and continuous renal replacement therapy were given, the patient died of multiple organ failure 15 days after the administration of piperacillin-tazobactam was stopped.

conclusionThis is the first complete description of the disease course and serological changes of piperacillin-induced immune hemolytic anemia, which is bound to help deepen the understanding of drug-induced immune hemolytic anemia and draw profound lessons from it.

Indexed as

Anemia, HemolyticMultiple Organ FailureAgedHumansHypertension, RenalMaleNephritisPiperacillinPiperacillin, Tazobactam Drug CombinationPiperacillinPiperacillin, Tazobactam Drug CombinationAntiglobulin testDrug-dependent antibodyDrug-induced immune hemolytic anemia (DIIHA)PiperacillinRenal dysfunction after administration

Identifiers

PMID37316798
PMCPMC10268429
OpenAlexW4380681148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.